NASDAQ:NTEC - Intec Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.60 -0.33 (-5.56 %) (As of 11/20/2018 06:48 AM ET)Previous Close$5.93Today's Range$5.60 - $5.9052-Week Range$3.55 - $7.50Volume155,764 shsAverage Volume154,346 shsMarket Capitalization$194.66 millionP/E Ratio-3.39Dividend YieldN/ABeta0.71 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel. Receive NTEC News and Ratings via Email Sign-up to receive the latest news and ratings for NTEC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTEC Previous Symbol CUSIPN/A Webwww.intecpharma.com Phone972-2586-4657 Debt Debt-to-Equity RatioN/A Current Ratio9.22 Quick Ratio9.22 Price-To-Earnings Trailing P/E Ratio-3.39 Forward P/E Ratio-4.21 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$2.26 per share Price / Book2.48 Profitability EPS (Most Recent Fiscal Year)($1.65) Net Income$-29,090,000.00 Net MarginsN/A Return on Equity-66.73% Return on Assets-60.24% Miscellaneous Employees70 Outstanding Shares32,830,000Market Cap$194.66 million OptionableOptionable Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions What is Intec Pharma's stock symbol? Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC." How were Intec Pharma's earnings last quarter? Intec Pharma (NASDAQ:NTEC) posted its quarterly earnings results on Friday, November, 9th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.03. View Intec Pharma's Earnings History. When is Intec Pharma's next earnings date? Intec Pharma is scheduled to release their next quarterly earnings announcement on Friday, March 8th 2019. View Earnings Estimates for Intec Pharma. What price target have analysts set for NTEC? 5 Wall Street analysts have issued 12-month target prices for Intec Pharma's stock. Their forecasts range from $8.50 to $16.00. On average, they anticipate Intec Pharma's stock price to reach $12.8750 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price. View Analyst Price Targets for Intec Pharma. What is the consensus analysts' recommendation for Intec Pharma? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intec Pharma. Has Intec Pharma been receiving favorable news coverage? News articles about NTEC stock have been trending very positive recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intec Pharma earned a news sentiment score of 3.1 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. Who are some of Intec Pharma's key competitors? Some companies that are related to Intec Pharma include Revance Therapeutics (RVNC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Radius Health (RDUS), Eagle Pharmaceuticals (EGRX), Cara Therapeutics (CARA), MacroGenics (MGNX), Crinetics Pharmaceuticals (CRNX), Karyopharm Therapeutics (KPTI), CannTrust (CNTTF), Inflarx (IFRX), CytomX Therapeutics (CTMX), Urogen Pharma (URGN), Vectura Group (VEGPF) and AC Immune (ACIU). Who are Intec Pharma's key executives? Intec Pharma's management team includes the folowing people: Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 51)Mr. Nir Sassi, Chief Financial Officer (Age 42)Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 49)Mr. Walt Addison Linscott, Chief Admin. Officer (Age 57)Anne Marie Fields, VP of Corp. Communications & Investor Relations When did Intec Pharma IPO? (NTEC) raised $30 million in an initial public offering on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO. Who are Intec Pharma's major shareholders? Intec Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Prosight Management LP (4.07%), Harel Insurance Investments & Financial Services Ltd. (2.01%), Migdal Insurance & Financial Holdings Ltd. (1.80%), ARK Investment Management LLC (0.33%), Laurion Capital Management LP (0.29%) and PNC Financial Services Group Inc. (0.23%). Which major investors are selling Intec Pharma stock? NTEC stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Which major investors are buying Intec Pharma stock? NTEC stock was purchased by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., Prosight Management LP, ARK Investment Management LLC, Laurion Capital Management LP, Migdal Insurance & Financial Holdings Ltd. and PNC Financial Services Group Inc.. How do I buy shares of Intec Pharma? Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Intec Pharma's stock price today? One share of NTEC stock can currently be purchased for approximately $5.60. How big of a company is Intec Pharma? Intec Pharma has a market capitalization of $194.66 million. The biotechnology company earns $-29,090,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Intec Pharma employs 70 workers across the globe. What is Intec Pharma's official website? The official website for Intec Pharma is http://www.intecpharma.com. How can I contact Intec Pharma? Intec Pharma's mailing address is 12 Hartom Street Har Hotzvim, Jerusalem L3, 9777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected] MarketBeat Community Rating for Intec Pharma (NASDAQ NTEC)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 156 (Vote Outperform)Underperform Votes: 204 (Vote Underperform)Total Votes: 360MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe NTEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/20/2018 by MarketBeat.com StaffFeatured Article: What is Cost of Debt?